- Home
- QMMM vs CRDF Comparison
QMMM vs CRDF Comparison
Compare QMMM & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QMMM
- CRDF
- Stock Information
- Founded
- QMMM 2005
- CRDF 1999
- Country
- QMMM Hong Kong
- CRDF United States
- Employees
- QMMM N/A
- CRDF N/A
- Industry
- QMMM
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QMMM
- CRDF Health Care
- Exchange
- QMMM NYSE
- CRDF Nasdaq
- Market Cap
- QMMM 93.3M
- CRDF 107.1M
- IPO Year
- QMMM 2024
- CRDF N/A
- Fundamental
- Price
- QMMM $9.08
- CRDF $2.79
- Analyst Decision
- QMMM
- CRDF Strong Buy
- Analyst Count
- QMMM 0
- CRDF 3
- Target Price
- QMMM N/A
- CRDF $9.67
- AVG Volume (30 Days)
- QMMM 938.9K
- CRDF 545.6K
- Earning Date
- QMMM 11-15-2024
- CRDF 10-31-2024
- Dividend Yield
- QMMM N/A
- CRDF N/A
- EPS Growth
- QMMM N/A
- CRDF N/A
- EPS
- QMMM N/A
- CRDF N/A
- Revenue
- QMMM $3,510,653.00
- CRDF $665,000.00
- Revenue This Year
- QMMM N/A
- CRDF $10.82
- Revenue Next Year
- QMMM N/A
- CRDF N/A
- P/E Ratio
- QMMM N/A
- CRDF N/A
- Revenue Growth
- QMMM 20.09
- CRDF 61.41
- 52 Week Low
- QMMM $3.00
- CRDF $0.94
- 52 Week High
- QMMM $9.75
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- QMMM N/A
- CRDF 59.98
- Support Level
- QMMM N/A
- CRDF $2.46
- Resistance Level
- QMMM N/A
- CRDF $2.88
- Average True Range (ATR)
- QMMM 0.00
- CRDF 0.17
- MACD
- QMMM 0.00
- CRDF 0.01
- Stochastic Oscillator
- QMMM 0.00
- CRDF 80.43
About QMMM QMMM HOLDINGS LIMITED
QMMM Holdings Ltd is a digital advertising and marketing production services company. It operates through its two wholly-owned subsidiaries. It has used interactive design, animation, art-tech and virtual technologies in over 500 commercial campaigns. The company has worked with large domestic and international banks, real estate developers, amusement parks, top international athletic apparel and footwear brands, and luxury cosmetic products and international brands for their advertising and creation work in Hong Kong. Its clients include local and international banks, real-estate developers, luxury brands, high fashion houses, and theme parks.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").